Amoéba is developing biological fungicides for treating diseases such as mildews and rusts, which have a major economic impact on the production globally of a wide range of crops. These novel fungicides are based on the characteristics of the Willaertia magna C2c Maky amoeba.
P&S Intelligence’s report noted that the global biocontrol agents market was worth c $4.9bn in 2021 and predicted it would increase to $13.6bn by 2030. According to McKinsey, the global skincare market was $200bn in 2022 and is expected to expand at a CAGR of 6% from 2022 to 2027. There are clear trends towards natural ingredients and premium products, with McKinsey forecasting that the premium end of the market should grow at an 8% CAGR, compared with 5% for the mass market and 6% for the global market. This trend should represent a significant tailwind to any Amoéba product sourced from a natural spring in the south of France.
Industrials |
Outlook
Industrials |
Update
Industrials |
Update
Industrials |
Update
Benoit Villers
Chairman
Jean-Francois Doucet
CEO
Forecast net debt (€m)
N/A
Forecast gearing ratio (%)
N/A
% | 1M | 3M | 12M |
---|---|---|---|
Actual | (12.9) | 1.0 | (28.3) |
Relative | (7.1) | 8.6 | (31.8) |
52 week high/low | €0.7/€0.4 |
FY23 grant income was €0.2m higher year-on-year, which was more than offset by a surge in operating costs of €1m to €7.3m, resulting in a widening of the EBIT loss by €0.8m to €6.6m. At end-FY23, Amoéba had €0.5m cash (€5.5m end-FY22) on its balance sheet and €4.9m debt (€2.4m end-FY22). The company is fully funded through CY24 via an existing debt facility with its lead shareholder. Amoéba expects to generate first revenues in 2026 and can meet early demand from existing production capacity.
Y/E Dec | Revenue (€m) | EBITDA (€m) | PBT (€m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2022A | 0.0 | (4.7) | (7.7) | (22.99) | N/A | N/A |
2023A | 0.0 | (5.6) | (6.9) | (14.10) | N/A | N/A |
2024E | 0.0 | (5.5) | (6.6) | (13.33) | N/A | N/A |
2025E | N/A | N/A | N/A | N/A | N/A | N/A |